Analysts Set Expectations for WVE Q1 Earnings

Wave Life Sciences Ltd. (NASDAQ:WVE) – Analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Wave Life Sciences in a note issued to investors on Wednesday, March 5th. HC Wainwright analyst A. Fein anticipates that the company will earn ($0.26) per share for the quarter. HC Wainwright has a “Buy” rating and a $22.00 price target on the stock. The consensus estimate for Wave Life Sciences’ current full-year earnings is ($1.14) per share. HC Wainwright also issued estimates for Wave Life Sciences’ Q2 2025 earnings at ($0.24) EPS, Q3 2025 earnings at ($0.22) EPS and Q4 2025 earnings at ($0.15) EPS.

Wave Life Sciences (NASDAQ:WVE) last posted its quarterly earnings data on Tuesday, March 4th. The company reported $0.17 EPS for the quarter, beating the consensus estimate of ($0.17) by $0.34. Wave Life Sciences had a negative return on equity of 280.57% and a negative net margin of 66.50%. The firm had revenue of $83.75 million during the quarter, compared to the consensus estimate of $25.60 million.

Several other analysts have also recently issued reports on WVE. Jefferies Financial Group assumed coverage on Wave Life Sciences in a report on Tuesday, February 25th. They issued a “buy” rating and a $26.00 target price for the company. Mizuho upped their target price on Wave Life Sciences from $19.00 to $22.00 and gave the company an “outperform” rating in a report on Thursday, November 21st. Truist Financial upped their target price on Wave Life Sciences from $17.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, November 12th. Finally, StockNews.com upgraded Wave Life Sciences from a “sell” rating to a “hold” rating in a report on Thursday, February 27th. Two equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Wave Life Sciences presently has an average rating of “Moderate Buy” and a consensus price target of $22.60.

Wave Life Sciences Stock Performance

NASDAQ WVE opened at $10.18 on Thursday. The business has a fifty day moving average price of $11.51 and a 200 day moving average price of $11.18. Wave Life Sciences has a one year low of $4.25 and a one year high of $16.74. The company has a market cap of $1.55 billion, a P/E ratio of -9.17 and a beta of -1.09.

Hedge Funds Weigh In On Wave Life Sciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Maverick Capital Ltd. boosted its holdings in Wave Life Sciences by 31.0% during the 3rd quarter. Maverick Capital Ltd. now owns 10,047,520 shares of the company’s stock valued at $82,390,000 after acquiring an additional 2,378,159 shares during the period. Driehaus Capital Management LLC boosted its holdings in Wave Life Sciences by 14.6% during the 4th quarter. Driehaus Capital Management LLC now owns 6,712,449 shares of the company’s stock valued at $83,033,000 after acquiring an additional 853,589 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in Wave Life Sciences by 63.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,098,866 shares of the company’s stock valued at $63,074,000 after acquiring an additional 1,972,262 shares during the period. Vanguard Group Inc. raised its position in Wave Life Sciences by 10.2% in the 4th quarter. Vanguard Group Inc. now owns 3,182,512 shares of the company’s stock valued at $39,368,000 after purchasing an additional 294,956 shares in the last quarter. Finally, Emerald Advisers LLC raised its position in Wave Life Sciences by 9.7% in the 4th quarter. Emerald Advisers LLC now owns 3,162,369 shares of the company’s stock valued at $39,119,000 after purchasing an additional 280,859 shares in the last quarter. 89.73% of the stock is currently owned by hedge funds and other institutional investors.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.